glisoxepide

Glisoxepide is a second-generation sulfonylurea oral antidiabetic drug used primarily for the management of type 2 diabetes mellitus. It acts as a hypoglycemic agent by stimulating insulin secretion from pancreatic beta cells through inhibition of ATP-sensitive potassium channel subunit Kir6.2/SUR1 complex (KATP) channels, leading to membrane depolarization, opening of voltage-gated calcium channels, and increased insulin release. Additionally, it may enhance peripheral insulin sensitivity and reduce serum glucagon levels. Glisoxepide also inhibits the uptake of bile acids into hepatocytes and is a specific inhibitor of the L-aspartate/L-glutamate antiport system[1][2][5][6].

Brand names

GlipiridePro-diaban

Other names

glisoxepid4-(4-beta-(5-methylisoxazol-3-carboxamidoethyl)phenylsulfonyl)-1,1-hexamethylenesemicarbazide